Details of Insulet's long-term vision and new details about Omnipod 6, alongside upgrades to existing systems and a fully closed-loop option for people with type 2 diabetes.
Image courtesy of Insulet Corp.
Insulet, parent company. of Omnipod, recently set out their long-term strategy focusing on accelerating innovation, expanding global access, and simplifying diabetes technology for both users and healthcare professionals. The announcements give the clearest picture yet of where Omnipod is heading over the next 3 years – and what that could mean for choice, connectivity, and ease of use.
What’s changing with Omnipod?
Insulet confirmed a three-stage plan running from 2026 to 2028, covering people with both type 1 and type 2 diabetes.
Omnipod 5 upgrades (planned for 2026)
Pending regulatory approval, Omnipod 5 is set to receive a series of enhancements designed to strengthen the existing ecosystem rather than replace it.
Key changes include:
-
Full CGM interoperability – Omnipod 5 is expected to work across all major CGMs, giving users and clinics more freedom of choice.
-
Deeper data insights – a new platform called Omnipod Discover will use machine learning to help people and healthcare professionals better understand glucose patterns and optimise therapy.
-
Smoother onboarding – Insulet says Discover will also help simplify setup and reduce friction when starting AID.
For many users, the promise of broader CGM compatibility alone is likely to be one of the most significant developments.
Omnipod 6: the next big step (targeted for 2027)
The headline announcement for the diabetes community is Omnipod 6, which Insulet describes as a “significant leap forward” in automated insulin delivery.
According to the company, Omnipod 6 will focus on:
-
An adaptive algorithm that learns from an individual’s glucose patterns over time
-
Universal CGM compatibility, with a configurable Pod designed to work across sensor systems
-
Improved comfort and usability, building on the tubeless form factor
-
A redesigned app and controller experience, aimed at simplifying setup and day-to-day use
Insulet says these changes are intended to reduce the burden of diabetes management while expanding access to AID for more people with type 1 and type 2 diabetes.
Fully closed loop for type 2 diabetes (planned for 2028)
Perhaps the most ambitious part of the roadmap is a fully closed-loop Omnipod system designed specifically for type 2 diabetes.
Planned for 2028, this system is intended to:
-
Work out of the box, with minimal setup
-
Remove the need for meal entry or manual input
-
Automate insulin delivery using an intelligent algorithm
If delivered as described, this could represent a major shift for people with type 2 diabetes who currently face high barriers to starting insulin pump therapy, and for healthcare professionals who may be hesitant to prescribe complex systems.
Looking ahead
With Omnipod 6 targeted for 2027 and a fully closed-loop type 2 system planned for 2028, Insulet is signalling that tubeless AID remains central to its future.
_______
Disclaimer
Blogs and publications on this website are independent of any involvement by medtech companies or diabetes related charities. To ensure there is no bias, we do not accept any products, freebies or other material from any medtech provider. Except where credited otherwise, all materials are copyright ©️What CGM.
What CGM is not associated or affiliated with Abbott or FreeStyle Libre. Content here and on our websitewww.whatcgm.com does not constitute medical advice or replace the relationship between you and healthcare professionals nor the advice you receive from them.
The author of this blog has type 1 diabetes and uses a CGM on NHS prescription.
Leave a comment (all fields required). Please note, we are unable to respond to individual comments posted here.